- Home
- NUW vs VNDA Comparison
NUW vs VNDA Comparison
Compare NUW & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUW
- VNDA
- Stock Information
- Founded
- NUW 2008
- VNDA 2002
- Country
- NUW United States
- VNDA United States
- Employees
- NUW N/A
- VNDA N/A
- Industry
- NUW Investment Managers
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- NUW Finance
- VNDA Health Care
- Exchange
- NUW Nasdaq
- VNDA Nasdaq
- Market Cap
- NUW 252.2M
- VNDA 249.4M
- IPO Year
- NUW N/A
- VNDA 2006
- Fundamental
- Price
- NUW $14.26
- VNDA $5.31
- Analyst Decision
- NUW
- VNDA Strong Buy
- Analyst Count
- NUW 0
- VNDA 2
- Target Price
- NUW N/A
- VNDA $16.50
- AVG Volume (30 Days)
- NUW 45.3K
- VNDA 454.6K
- Earning Date
- NUW 01-01-0001
- VNDA 11-05-2025
- Dividend Yield
- NUW 3.66%
- VNDA N/A
- EPS Growth
- NUW N/A
- VNDA N/A
- EPS
- NUW N/A
- VNDA N/A
- Revenue
- NUW N/A
- VNDA $203,467,000.00
- Revenue This Year
- NUW N/A
- VNDA $15.45
- Revenue Next Year
- NUW N/A
- VNDA $37.82
- P/E Ratio
- NUW N/A
- VNDA N/A
- Revenue Growth
- NUW N/A
- VNDA 11.78
- 52 Week Low
- NUW $12.45
- VNDA $3.81
- 52 Week High
- NUW $14.44
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- NUW 70.31
- VNDA 66.48
- Support Level
- NUW $13.97
- VNDA $4.84
- Resistance Level
- NUW $14.25
- VNDA $5.48
- Average True Range (ATR)
- NUW 0.10
- VNDA 0.21
- MACD
- NUW 0.01
- VNDA 0.07
- Stochastic Oscillator
- NUW 92.22
- VNDA 86.11
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.